Deeptech startup Plenome Technologies raises ₹6.5 crore from Indian and global investors

In a significant development in India’s deeptech ecosystem, Plenome Technologies, a promising startup focused on revolutionizing genomic research and precision diagnostics, has secured ₹6.5 crore in funding from a mix of Indian and international investors. The round marks a milestone for the Bengaluru-based firm as it aims to accelerate R&D and commercial deployment of its next-gen health technology products.

This capital infusion reaffirms the growing investor confidence in India’s deeptech sector, particularly in companies that combine artificial intelligence, biotech, and genomics to solve complex real-world challenges.

About Plenome Technologies

Founded in 2021 by Dr. Pranav Mishra, a biotech researcher with over 15 years of experience in computational biology and diagnostics, Plenome Technologies operates at the intersection of genomics, AI, and healthcare innovation. The company is developing a proprietary platform that enables ultra-precise genome sequencing, molecular diagnostics, and early disease prediction models using bioinformatics and AI algorithms.

Plenome’s vision is to make genomic diagnostics accessible and affordable for the Indian population, while also supporting global research institutions with its AI-powered genome analysis tools.

Investor Breakdown: Who’s Backing Plenome?

The ₹6.5 crore seed funding round saw participation from both domestic and international investors, including early-stage VC firms, health-tech focused angels, and biotech researchers turned investors from the US, UK, and Singapore.

This is Plenome’s first major institutional round after bootstrapping operations for nearly two years. The company has previously received a DST startup grant, which enabled early-stage prototyping.

Focus Areas and Proprietary Technology

Plenome’s flagship product is a machine-learning powered genomics analysis suite, known as PlenoMap, which delivers rapid and precise DNA/RNA mapping, anomaly detection, and risk assessment for critical diseases like cancer, diabetes, neurological disorders, and rare genetic syndromes.

Key features of PlenoMap:

• Ultra-fast genomic alignment engine (20x faster than traditional tools)
• Multi-modal health data integration
• AI-based mutation risk scoring
• Data anonymization and patient privacy architecture

Plenome also collaborates with clinics, pathology labs, and research hospitals to offer co-branded diagnostic solutions in oncology and hereditary disease detection.

Use of Funds

The fresh ₹6.5 crore capital will be strategically allocated to accelerate product development and market readiness.

The company is also eyeing international regulatory approvals, especially from the FDA (US) and EMA (Europe) to enter clinical genomics markets abroad.

Founder’s Vision

Speaking about the fundraise, Dr. Pranav Mishra, CEO and Co-founder, said:

“We’re entering a new era where biology meets data science. With this support from our investors, we can accelerate the democratization of high-precision genomics in India and beyond. Our mission is to enable a healthcare ecosystem where diseases can be predicted before they manifest, and treatments can be personalized with confidence.”

Genomics and DeepTech in India: Market Outlook

India’s deeptech startup landscape has seen a major push post-2020 with increasing investor interest in AI, biotech, medtech, and space tech sectors. Genomics, in particular, is witnessing rapid momentum with startups like MapmyGenome, MedGenome, and Strand Life Sciences already making strides.

Government schemes like Biotech Ignition Grant (BIG) and Startup India DeepTech Seed Fund are further nurturing early-stage companies working in this space.

Strategic Collaborations and Future Plans

Plenome is currently in talks with multiple hospitals, genetic counselors, and health insurers for strategic partnerships. The company aims to pilot its PlenoMap Oncology Suite in 15 hospitals across India by the end of FY2025.

Key strategic priorities for 2025–2026:

• Launch of PlenoDx kits for cancer risk assessment
• Expansion to Southeast Asia and MENA regions
• Onboarding of 50+ genomics labs for B2B SaaS model
• Filing of five international patents

Competitor Analysis: Where Plenome Stands

Plenome distinguishes itself by combining speed, affordability, and deep AI capability into its genomics offering—targeted particularly at research labs and early diagnostic centers.

Challenges Ahead

While investor sentiment is bullish, scaling in genomics involves several hurdles:

• Data privacy concerns
• Regulatory compliance
• High-end talent acquisition
• Infrastructure costs for genome storage and analysis

Plenome is addressing these via a zero-knowledge architecture, strategic data localization, and tapping into India’s biotech talent pool through IITs and IISc.

Disclaimer: The content provided is for informational purposes only and should not be construed as financial, medical, or investment advice. Readers are advised to perform their own research or consult professionals before making any business or investment decisions.